Baseline characteristics
| Control-group n=101 | iAR-group n=101 | iLE-group n=101 | |
| Age | 66 (59–70) | 66 (58–71) | 64 (59–71) |
| Gender (male) | 86% | 82% | 85% |
| More than one CVD location | 11% | 10% | 10% |
| Current smoker | 17% | 16% | 9% |
| Years clinically manifest CVD | 0 (0–10) | 0 (0–10) | 3 (0–10) |
| Diabetes mellitus | 14% | 27% | 23% |
| LDL-cholesterol (mmol/L) | 2.0 (1.7–2.4) | 2.0 (1.6–2.4) | 2.0 (1.6–2.5) |
| LDL-cholesterol>1.8 mmol/L | 65% | 67% | 60% |
| Already on maximum statin therapy | 1.3% | 1.0% | 1.0% |
| Creatinin (umol/L) | 84 (78–93) | 83 (75–96) | 85 (75–94) |
| Systolic blood pressure (mm Hg) | 131 (121–142) | 131 (121–143) | 129 (122-142) |
| Number of medications per day | 5 (4–6) | 6 (4–9) | 6 (4–8) |
| Disutility | 61 (9–97) | 61 (5–97) | 61 (9–97) |
| Adequate health literacy | 83% | 83% | 81% |
Data are reported as mean±SD, median (IQR) or (%). CVD locations defined as coronary artery disease, peripheral artery disease or abdominal aortic aneurysm in addition to cerebrovascular disease. Health literacy was based on the Newest Vital Sign score in the baseline questionnaire.28 Disutility is months required to offset inconvenience of daily pill-taking of an idealised medication.8 Number of medications excludes over the counter medications, (nasal) sprays and topical medications. Maximum therapy was atorvastatin 80 mg.
CVD, cardiovascular disease; iAR-group, 10-year risk; iLE-group, CVD-free life-expectancy; LDL, low-density lipoprotein.